Welcome to our dedicated page for DR REDDYS LABORATORIES SEC filings (Ticker: RDY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on DR REDDYS LABORATORIES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into DR REDDYS LABORATORIES's regulatory disclosures and financial reporting.
DR REDDYS LABORATORIES LTD director Shikha Sanjaya Sharma has filed an initial Form 3 reporting beneficial ownership. The filing lists her status as a director of the company and shows no reported transactions, share purchases or sales, and no derivative positions at this time.
DR REDDYS LABORATORIES LTD director Sanjiv Soshil Mehta has filed an initial Form 3, which is a baseline statement of his beneficial ownership in the company’s securities. The filing does not report any stock purchases, sales, option exercises, or other transactions.
DR REDDYS LABORATORIES LTD director files initial ownership report
Penny Chan Wan, a director of DR REDDYS LABORATORIES LTD, filed an initial Form 3 reporting beneficial ownership in the company’s securities. The summary data in this filing shows no reported transactions or derivative positions and no separate holding entries at this time.
DR REDDYS LABORATORIES LTD director Kodumudi Pranatharthi Haran Krishnan has filed a Form 3, which is an initial statement of beneficial ownership for company insiders. This filing establishes his official status as a director and sets the baseline record of his holdings for future Form 4 or Form 5 updates.
DR REDDYS LABORATORIES LTD director Leo Puri has filed an initial insider ownership report on Form 3. This filing establishes his status as a reporting insider of the company but does not list any specific transactions, focusing instead on baseline disclosure and compliance with insider reporting rules.
DR REDDYS LABORATORIES LTD director Arun Madhavan Kumar filed an initial Form 3, which is a required statement of beneficial ownership for insiders. This filing does not list any transactions or holdings and simply establishes his status as a reporting person for future ownership disclosures.
Dr. Reddy’s Laboratories Limited has allotted 3,675 equity shares of Re.1 each on March 26, 2026 to eligible employees who exercised stock options under the Dr. Reddy’s Employees ADR Stock Option Scheme, 2007. These equity shares rank pari passu with the company’s existing shares, and total issued shares after this allotment are stated as 83,46,57,970, with a corresponding issued share capital of Rs. 83,46,57,970.
Dr. Reddy’s Laboratories Limited filed a Form 6-K to inform investors that its Board has approved an amended Code of Practices and Procedures for Fair Disclosures of Un-published Price Sensitive Information under India’s SEBI insider trading rules.
The code designates the Head of Investor Relations as Chief Investor Relations Officer, responsible for prompt, uniform disclosure of any unpublished price sensitive information to all stock exchanges and on the company website, and for quickly correcting any inadvertent selective disclosure. It restricts use of such information to a strict “need to know” basis, explicitly bars sharing it via social media, and allows sharing only for legitimate purposes with partners and advisors who are then treated as insiders.
The company will maintain a structured digital database of who shares and receives unpublished price sensitive information, including identifiers such as PAN, for at least eight years and longer if required for SEBI proceedings. The Board will review and update the code to align with future changes in SEBI regulations and listing requirements.
Dr. Reddy’s Laboratories Limited has scheduled a Board of Directors meeting for May 12, 2026 to consider the audited standalone and consolidated financial results for the quarter and financial year ending March 31, 2026.
The company also announced that, under SEBI (Prohibition of Insider Trading) Regulations, the trading window for dealing in its securities will be closed from March 25, 2026 to May 14, 2026, both days inclusive.
Dr. Reddy’s Laboratories has launched Obeda®, India’s first Drugs Controller General of India (DCGI)‑approved generic semaglutide injection for managing type 2 diabetes. The product marks a Day‑1 entry after patent expiry and targets a country with more than 101 million adults living with diabetes.
Obeda® is available in 2 mg and 4 mg pre‑filled disposable pens for once‑weekly subcutaneous use, with each pen delivering at least four weekly doses at a cost of INR 4,200 per month. A Phase III trial in 312 participants showed non‑inferior efficacy and safety versus the innovator, and Dr. Reddy’s is pairing the launch with the SemaKare™ patient‑support program and plans for broader GLP‑1 portfolios and metabolic centres of excellence in India.